Company / Gross Margin
Gilead Sciences Gross Margin History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
16.3%
FY2019
5-year range
-
FY2016-FY2019
Trend
+23.5%
vs FY2018
Sector context
#29 of 28
Health Care
What the data says
Among 28 Health Care companies, Gilead Sciences is in the bottom -4% for gross margin. Gross Margin returned to growth in FY2019 after 2 years of decline, reaching 16.3%.
Based on SEC 10-K filings.
16.3% in FY2019 with a 3-year CAGR of -9.8%.
Declined from 16.6% to 16.3% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -9.8pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom -4% in Health CareTop 104% of 28This company 16.3% Sector average 60.3%
▼
-73.0% below sector average
Key checks
Key Insights
- In FY2019, gross margin increased 23.5% year-over-year.
- Currently 44.0pp below the Health Care sector average.
Company context
Key Data Points
- Strong profit margin: 27.9%
- Strong return on equity: 37.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | 16.3% | +23.5% |
| FY2018 | 13.2% | -20.8% |
| FY2017 | 16.6% | -36.3% |
| FY2016 | 26.1% | +30.4% |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026